Investigational drug · Phase 2
TAK-242
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "TAK-242"
First trial start
2026
Jun 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAK-242", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute-On-Chronic Liver Failure
- Alcoholic Hepatitis
- Liver Cirrhosis, Alcoholic
Approved drugs for the same conditions: Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TAK-242" as an intervention, largest first.
- Efficacy & Safety of Resatorvid in Adults With Severe SepsisPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00143611 · 277 participants · Start Sep 2005 · Primary completion Feb 2007
Drug: Resatorvid; Resatorvid and 1 more · For: Sepsis
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 144 sites in all
- A-TANGO Phase 2 StudyRecruiting
Yaqrit LtdIndustry
NCT06890039 · 78 participants (planned) · Start Jun 29, 2026 · Primary completion Aug 31, 2028
Drug: Placebo; TAK-242 and 1 more · For: Acute-On-Chronic Liver Failure; Alcoholic Hepatitis; Liver Cirrhosis, Alcoholic
Sites: London, United Kingdom
- Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory FailurePivotal-lookingTerminated
TakedaTakeda (TAK)
NCT00633477 · 18 participants · Start Feb 2008 · Primary completion Feb 2009
Drug: Resatorvid; Placebo · For: Sepsis
Sites: Nagasaki, Japan
Akaza Bioscience LtdIndustry
NCT04620148 · 4 participants · Start Nov 12, 2020 · Primary completion Mar 31, 2022
Drug: TAK-242; Placebo · For: Acute-On-Chronic Liver Failure
Sites: London, United Kingdom; Nottingham, United Kingdom; Plymouth, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Integrative network pharmacology, machine learning, and experimental validation identify the TLR4/NF-κB/NLRP3 axis as a potential mechanism underlying the therapeutic effects of Lingguizhugan decoction in Alzheimer's disease.
Hu D, Li D, He L, et al. · J Ethnopharmacol 2027
- Flower aqueous extract of Hylocereus undatus (Haw.) Britton & Rose attenuates influenza infection: involvement of the TLR4/MyD88/NF-κB signaling axis.
Wang X, Jiang L, Liang F, et al. · J Ethnopharmacol 2027
- Jiu-Wei-Yong-An decoction alleviates atopic dermatitis by suppressing TLR4/MyD88/NF-κB signaling pathway.
Zhang H, Gu Q, Meng Y, et al. · J Ethnopharmacol 2027
- Exertional heat stroke induces liver injury through the activation of the TLR4/NF-κB signaling pathway.
Teng L, Wu H, Cai F, et al. · Biochem Biophys Rep 2026
- Large-scale organoid-derived cyst cultures as a drug discovery platform for polycystic kidney disease.
Vanichapol T, Wangford R, Mishra S, et al. · Kidney Int 2026
- Nogo-B deletion mitigates mitochondrial dynamics imbalance in cerebral ischemia/reperfusion injury via the TLR4/ERK pathway.
Fan T, Xu R, Hu Z, et al. · Exp Neurol 2026
Also in development for Acute-On-Chronic Liver Failure
- F573Phase 21 trial
Beijing Continent Pharmaceutical Co, Ltd. · Acute Liver Failure, Acute-On-Chronic Liver Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.